ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.150,71
-0,10%
S&P 500
5.303,27
0,12%
US Dollar vs BRL
5,1047
-0,50%
Bitcoin
67.004,77
2,71%
Brent Oil
83,76
0,67%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Anebulo Pharmaceuticals Inc (ANEB)

  7. Anebulo Pharmaceuticals Inc (ANEB) Notícias

ANEB

Anebulo Pharmaceuticals (ANEB)

Anebulo Pharmaceuticals Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:ANEB
DataHoraFonteTítuloCódigoCompanhia
15/05/202417:31Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ANEBAnebulo Pharmaceuticals Inc
15/05/202417:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANEBAnebulo Pharmaceuticals Inc
15/05/202414:05Business WireAnebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent UpdatesNASDAQ:ANEBAnebulo Pharmaceuticals Inc
13/02/202418:05Business WireAnebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent UpdatesNASDAQ:ANEBAnebulo Pharmaceuticals Inc
14/11/202318:05Business WireAnebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent UpdatesNASDAQ:ANEBAnebulo Pharmaceuticals Inc
30/10/202310:31Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:ANEBAnebulo Pharmaceuticals Inc
30/10/202310:22Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ANEBAnebulo Pharmaceuticals Inc
19/10/202318:18Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:ANEBAnebulo Pharmaceuticals Inc
06/10/202317:06Business WireAnebulo Pharmaceuticals Announces New CEONASDAQ:ANEBAnebulo Pharmaceuticals Inc
06/10/202317:06Business WireAnebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of DirectorsNASDAQ:ANEBAnebulo Pharmaceuticals Inc
02/10/202318:01Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ANEBAnebulo Pharmaceuticals Inc
22/09/202317:05Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ANEBAnebulo Pharmaceuticals Inc
20/09/202317:29Business WireAnebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent UpdatesNASDAQ:ANEBAnebulo Pharmaceuticals Inc
30/08/202309:00Business WireAnebulo Pharmaceuticals to Present at Upcoming Investor and Scientific ConferencesNASDAQ:ANEBAnebulo Pharmaceuticals Inc
21/08/202309:00Business WireAnebulo Receives Positive Feedback from FDA on Path to Advance Phase 3 Clinical Development of ANEB-001 and Completes Dosing of Phase 2 ExtensionNASDAQ:ANEBAnebulo Pharmaceuticals Inc
11/05/202317:07Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ANEBAnebulo Pharmaceuticals Inc
11/05/202309:16Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ANEBAnebulo Pharmaceuticals Inc
11/05/202309:00PR Newswire (US)Anebulo Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Recent UpdatesNASDAQ:ANEBAnebulo Pharmaceuticals Inc
04/04/202319:33Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:ANEBAnebulo Pharmaceuticals Inc
28/03/202309:00PR Newswire (US)Anebulo Pharmaceuticals Announces Positive Complete Phase 2 Clinical Data Demonstrating Potential of ANEB-001 as a Treatment for Acute Cannabinoid IntoxicationNASDAQ:ANEBAnebulo Pharmaceuticals Inc
08/03/202310:00PR Newswire (US)Anebulo Pharmaceuticals Expands its Integrated and Outsourced SolutionsNASDAQ:ANEBAnebulo Pharmaceuticals Inc
10/02/202310:38Business Wire Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2023 Financial Results and Recent UpdatesNASDAQ:ANEBAnebulo Pharmaceuticals Inc
09/01/202310:00Business WireAnebulo Pharmaceuticals Announces Completion of Dosing and Preliminary Data from Part B of its Phase 2 Study of ANEB-001 for Acute Cannabinoid IntoxicationNASDAQ:ANEBAnebulo Pharmaceuticals Inc
14/11/202208:13Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:ANEBAnebulo Pharmaceuticals Inc
10/11/202210:00Business WireAnebulo Pharmaceuticals Reports First Quarter Fiscal Year 2023 Financial Results and Recent UpdatesNASDAQ:ANEBAnebulo Pharmaceuticals Inc
02/11/202217:07Edgar (US Regulatory)Securities Registration Statement (s-1)NASDAQ:ANEBAnebulo Pharmaceuticals Inc
01/11/202217:00Business WireAnebulo Pharmaceuticals Announces Appointment of Nat Calloway, Ph.D., to Board of DirectorsNASDAQ:ANEBAnebulo Pharmaceuticals Inc
17/10/202210:03Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:ANEBAnebulo Pharmaceuticals Inc
11/10/202207:01Edgar (US Regulatory)Small Company Offering and Sale of Securities Without Registration (d)NASDAQ:ANEBAnebulo Pharmaceuticals Inc
03/10/202220:54Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ANEBAnebulo Pharmaceuticals Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:ANEB

Seu Histórico Recente

BOV
BIHE39
BlackRock Institutional ...
TSX
ATD.A
Alimentation Couche Tard
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados